BDPARIB contains rucaparib, a targeted anticancer medication from the PARP inhibitor class. It is designed for the treatment of certain advanced cancers, particularly those associated with inherited or acquired mutations in DNA repair genes such as BRCA1 and BRCA2. It offers a personalised treatment approach by focusing on the unique vulnerabilities of cancer cells, aiming to prolong remission and improve quality of life in selected patients.

Mechanism of Action
Rucaparib inhibits an enzyme called poly ADP ribose polymerase or PARP, which is essential for repairing damaged DNA. In cancer cells with mutations in BRCA genes or related repair pathways, the inhibition of PARP causes an accumulation of DNA damage that the cells cannot fix. This ultimately leads to cancer cell death while sparing most healthy cells, which still have intact repair mechanisms. This concept, known as synthetic lethality, underpins rucaparib’s therapeutic strategy.

Uses
BDPARIB is primarily used to treat ovarian and fallopian tube cancers that have recurred or shown sensitivity to platinum-based chemotherapy. It may also be used as a maintenance therapy to help prevent the return of cancer after an initial response. In addition, it has been used for certain prostate cancers associated with homologous recombination repair gene mutations. Genetic testing is often done to identify patients who are most likely to benefit from rucaparib treatment.

Adverse Effects
The most common side effects include fatigue, nausea, vomiting, loss of appetite, and taste changes. Some individuals may experience anemia, low platelet counts, or low white blood cell counts, which require regular blood monitoring. Liver enzyme changes and increased cholesterol levels can also occur. Rare but serious risks include the potential development of secondary blood disorders like myelodysplastic syndrome or acute myeloid leukemia. Close follow-up and early reporting of unusual symptoms help ensure safe and effective use.